APELLIS PHARMACEUTICALS, INC. — Revenue by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/860ed9db-5679-42fe-92e7-7287a0be96a1/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $1.0B | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-065179 |
| FY 2024 | $781.4M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029507 |
| FY 2023 | $396.6M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-020614 |
| FY 2022 | $75.4M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-003438 |
| FY 2021 | $66.6M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-007606 |
| FY 2020 | $250.6M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-008800 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
APELLIS PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income